US-based biotechnology company Imunon has reported positive results from its Phase II OVATION 2 trial of IMNN-001 for ovarian ...

Consistent OS Efficacy Benefit Across Multiple Treatment Subgroups Demonstrates IMNN-001’s Ability to Recruit a Powerful Anti-Cancer Immune Response  Results, presented simultaneously in oral ...

As I mark my first year as President and CEO of IMUNON, I am thrilled to share the progress we have made in advancing our mission to transform cancer treatment. With robust fundamentals and ...

IMNN READ THE FULL IMNN RESEARCH REPORT Business Update Momentum Continues with Presentations at ASCO and ESMO Imunon, Inc.

These 10 Firms Crushed The Market Last Week. In this article, we are going to take a look at where Imunon, Inc. (NASDAQ:IMNN) ...

Xilio Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery and development of tumor-activated immuno-oncology therapies. The company’s checkpoint inhibitor ...